4 completed, 1 withdrawn. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
Follow LY2940094: new trials by email Literature Review of LY2940094 trials Research Report on LY2940094
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigating the Protective Impact of LY-2940094 on Stress-induced Depression- and Anxiety-related Phenotypes in Humans Nociceptin Receptor Antagonist (LY-2940094), DS8R Biphasic Constant Current Stimulator - Depression - Major Depressive Disorder, Anxiety | Phase 2 | Withdrawn | Mclean Hospital | 2025-06-01 | 2025-09-25 | |
| A Study of LY2940094 in Participants With Alcohol Dependency LY2940094, Placebo - Alcoholism | Phase 2 | Completed | BlackThorn Therapeutics, Inc. | 88 | 2013-07-01 | 2017-02-03 |
| Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD) LY2940094, Placebo - Major Depressive Disorder | Phase 2 | Completed | BlackThorn Therapeutics, Inc. | 136 | 2012-11-01 | 2017-02-03 |
| A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects LY2940094 - Depression | Phase 1 | Completed | BlackThorn Therapeutics, Inc. | 12 | 2011-07-01 | 2017-02-03 |
| A Study of LY2940094 in Major Depressive Disorder LY2940094, Placebo - Major Depressive Disorder | Phase 1 | Completed | BlackThorn Therapeutics, Inc. | 66 | 2010-12-01 | 2017-02-03 |
Depression (2) · Depressive Disorder, Major (2) · Alcoholism (1) · Anxiety Disorders (1)
BlackThorn Therapeutics, Inc. (4) · Mclean Hospital (1)
Canada (2) · United States (2)
P50MH119467 (1)